دورية أكاديمية
أعرض في EDS

Rates of unanticipated premalignant and malignant lesions at the time of hysterectomy performed for pelvic organ prolapse in an underscreened population.

التفاصيل البيبلوغرافية
العنوان: Rates of unanticipated premalignant and malignant lesions at the time of hysterectomy performed for pelvic organ prolapse in an underscreened population.
المؤلفون: Barakzai S; Departments of Obstetrics and Gynecology (Dr Barakzai, Ms Koltun-Baker, Mr Melville, and Drs Rangel and Dancz)., Koltun-Baker E; Departments of Obstetrics and Gynecology (Dr Barakzai, Ms Koltun-Baker, Mr Melville, and Drs Rangel and Dancz)., Melville SJF; Departments of Obstetrics and Gynecology (Dr Barakzai, Ms Koltun-Baker, Mr Melville, and Drs Rangel and Dancz)., Rangel E; Departments of Obstetrics and Gynecology (Dr Barakzai, Ms Koltun-Baker, Mr Melville, and Drs Rangel and Dancz)., Dahl M; Urology (Dr Dahl), University of Southern California, Los Angeles, CA., Dancz CE; Departments of Obstetrics and Gynecology (Dr Barakzai, Ms Koltun-Baker, Mr Melville, and Drs Rangel and Dancz).
المصدر: AJOG global reports [AJOG Glob Rep] 2023 May 06; Vol. 3 (2), pp. 100217. Date of Electronic Publication: 2023 May 06 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101777907 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-5778 (Electronic) Linking ISSN: 26665778 NLM ISO Abbreviation: AJOG Glob Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [New York] : Elsevier Inc., [2021]-
مستخلص: Background: The rate of unanticipated premalignant or malignant pathology at the time of hysterectomy performed for pelvic organ prolapse has been previously reported to be 0.2%. It is not known whether this rate is similar in patients with limited access to regular medical care.
Objective: This study aimed to describe the rates of unanticipated premalignancy and malignancy at the time of hysterectomy performed for pelvic organ prolapse in an underscreened population and to determine the risk factors for unanticipated pathology.
Study Design: Hysterectomies performed for pelvic organ prolapse at a large public hospital between July 2007 and July 2019 were reviewed. Patients undergoing surgery for malignancy or premalignancy were excluded. Medical records were reviewed for demographic information, medical history, preoperative workup, and final pathology. Frequencies of abnormal pathologies were calculated. Demographic and screening factors were correlated with pathologic findings using the Fisher exact test or Mann-Whitney U test, as appropriate. This study was approved by the institutional review board.
Results: Between 2007 and 2019, 759 cases of pelvic organ prolapse were identified. Of 759 patients, 667 (87.9%) self-identified as Hispanic. The median age was 57 years old, and 505 of 759 patients (66.5%) were in the postmenopausal stage. Abnormal uterine bleeding history was present in 217 of 759 patients (28.6%). Of 759 patients, 493 (65.4%) underwent preoperative ultrasonography, and 290 (38.3%) underwent preoperative endometrial biopsy. Of the 744 uterine specimens that had available histology results, there were 2 cases of endometrial hyperplasia and 1 case of endometrial cancer. Of the 729 cervical specimens that were available for review, there was 1 case of intraepithelial neoplasia and 2 cases of cervical cancer. In the 246 patients who underwent oophorectomy, no ovarian malignancy was found.
Conclusion: For patients undergoing hysterectomy for pelvic organ prolapse in an underscreened population, the rates of endometrial dysplasia or cancer were 0.40% (3/744), and the rates of cervical dysplasia or cancer were 0.42% (3/729). Our results underscore the importance of considering screening history when interpreting preoperative cervical and endometrial cancer screening. Consideration of higher negative predictive value tests, such as cytology with human papillomavirus cotesting and preoperative counseling on the risks and management strategies of unanticipated premalignancy or malignancy within this population may be reasonable.
(© 2023 Published by Elsevier Inc.)
References: J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686)
Female Pelvic Med Reconstr Surg. 2014 Mar-Apr;20(2):113-5. (PMID: 24566217)
Int J Gynaecol Obstet. 2017 May;137(2):123-128. (PMID: 28170091)
Int J Gynecol Cancer. 2016 Jan;26(1):149-55. (PMID: 26332395)
Acta Cytol. 2017;61(6):434-440. (PMID: 28738387)
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):381-7. (PMID: 20142239)
Am J Obstet Gynecol. 2019 Jul;221(1):39.e1-39.e14. (PMID: 30853364)
Eur J Obstet Gynecol Reprod Biol. 2018 Apr;223:108-112. (PMID: 29518640)
Female Pelvic Med Reconstr Surg. 2016 Jul-Aug;22(4):190-3. (PMID: 26945272)
Int Urogynecol J. 2012 Jul;23(7):913-7. (PMID: 22398824)
Neurourol Urodyn. 2011 Jun;30(5):729-34. (PMID: 21661021)
Female Pelvic Med Reconstr Surg. 2021 Feb 1;27(2):e282-e289. (PMID: 32604198)
Geburtshilfe Frauenheilkd. 2015 Feb;75(2):135-136. (PMID: 25797956)
CA Cancer J Clin. 2021 Nov;71(6):466-487. (PMID: 34545941)
Female Pelvic Med Reconstr Surg. 2016 Sep-Oct;22(5):332-5. (PMID: 27171317)
J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660)
Am J Obstet Gynecol. 2010 May;202(5):507.e1-4. (PMID: 20452498)
فهرسة مساهمة: Keywords: Papanicolaou test; cervical cancer; endometrial biopsy; endometrial cancer; pelvic organ prolapse; screening; underserved
تواريخ الأحداث: Date Created: 20230605 Latest Revision: 20230607
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10232886
DOI: 10.1016/j.xagr.2023.100217
PMID: 37275440
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-5778
DOI:10.1016/j.xagr.2023.100217